Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms

Tsz-Kan Fung; Alice M S Cheung; Yok-Lam Kwong; Raymond Liang; Anskar Y H Leung

doi:10.1016/j.leukres.2010.01.028

Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms

Tsz-Kan Fung, Alice M S Cheung, Yok-Lam Kwong, Raymond Liang, Anskar Y H Leung

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

We evaluated the NOD/SCID engraftment of CD34(+) cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34(+) cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET.

Original language	English
Pages (from-to)	1390-4
Number of pages	5
Journal	Leukemia Research
Volume	34
Issue number	10
DOIs	https://doi.org/10.1016/j.leukres.2010.01.028
Publication status	Published - Oct 2010

Keywords

Adult
Aged
Aged, 80 and over
Animals
Antigens, CD34
Female
Hematopoietic Stem Cell Transplantation
Humans
Janus Kinase 2
Male
Mice
Mice, Inbred NOD
Mice, SCID
Middle Aged
Mutation
Polycythemia Vera
Primary Myelofibrosis
Thrombocythemia, Essential

Access to Document

10.1016/j.leukres.2010.01.028

Cite this

@article{c5fa51e728bc469ab59ee9037b4a8805,

title = "Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms",

abstract = "We evaluated the NOD/SCID engraftment of CD34(+) cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34(+) cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET.",

keywords = "Adult, Aged, Aged, 80 and over, Animals, Antigens, CD34, Female, Hematopoietic Stem Cell Transplantation, Humans, Janus Kinase 2, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Mutation, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential",

author = "Tsz-Kan Fung and Cheung, {Alice M S} and Yok-Lam Kwong and Raymond Liang and Leung, {Anskar Y H}",

year = "2010",

month = oct,

doi = "10.1016/j.leukres.2010.01.028",

language = "English",

volume = "34",

pages = "1390--4",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms

AU - Fung, Tsz-Kan

AU - Cheung, Alice M S

AU - Kwong, Yok-Lam

AU - Liang, Raymond

AU - Leung, Anskar Y H

PY - 2010/10

Y1 - 2010/10

N2 - We evaluated the NOD/SCID engraftment of CD34(+) cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34(+) cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET.

AB - We evaluated the NOD/SCID engraftment of CD34(+) cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34(+) cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Animals

KW - Antigens, CD34

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Janus Kinase 2

KW - Male

KW - Mice

KW - Mice, Inbred NOD

KW - Mice, SCID

KW - Middle Aged

KW - Mutation

KW - Polycythemia Vera

KW - Primary Myelofibrosis

KW - Thrombocythemia, Essential

U2 - 10.1016/j.leukres.2010.01.028

DO - 10.1016/j.leukres.2010.01.028

M3 - Article

C2 - 20170959

SN - 0145-2126

VL - 34

SP - 1390

EP - 1394

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms

Abstract

Keywords

Access to Document

Fingerprint

Cite this